The Kidney Protective Effects of the Sodium–Glucose Cotransporter-2 Inhibitor, Dapagliflozin, Are Present in Patients With CKD Treated With Mineralocorticoid Receptor Antagonists

INTRODUCTION: Mineralocorticoid receptor antagonists (MRAs) and sodium–glucose cotransporter-2 (SGLT2) inhibitors reduce the risk of kidney failure in chronic kidney disease (CKD). We performed an analysis of the Dapagliflozin and Prevention of Adverse Outcomes in Chronic Kidney Disease (DAPA-CKD) t...

Descripción completa

Detalles Bibliográficos
Autores principales: Provenzano, Michele, Jongs, Niels, Vart, Priya, Stefánsson, Bergur V., Chertow, Glenn M., Langkilde, Anna Maria, McMurray, John J.V., Correa-Rotter, Ricardo, Rossing, Peter, Sjöström, C. David, Toto, Robert D., Wheeler, David C., Heerspink, Hiddo J.L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Clinical Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8897688/
https://www.ncbi.nlm.nih.gov/pubmed/35257056
http://dx.doi.org/10.1016/j.ekir.2021.12.013

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8897688/
https://www.ncbi.nlm.nih.gov/pubmed/35257056
http://dx.doi.org/10.1016/j.ekir.2021.12.013

Ejemplares similares